| Drug Name |
Vildagliptin |
| Drug ID |
BADD_D02357 |
| Description |
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired.[A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are incretin hormones that promote insulin secretion and regulate blood glucose levels. Elevated levels of GLP-1 and GIP consequently results in improved glycemic control.[L32803] In clinical trials, vildagliptin has a relatively low risk of hypoglycemia.[A232488]
Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea, or a thiazolidinedione in patients with inadequate glycemic control following monotherapy. It is marketed as Galvus.[L32803] Vildagliptin is also available as Eucreas, a fixed-dose formulation with metformin for adults in who do not adequately glycemic control from monotherapy.[L32813] Vildagliptin is currently under investigation in the US. |
| Indications and Usage |
Used to reduce hyperglycemia in type 2 diabetes mellitus. |
| Marketing Status |
Not Available |
| ATC Code |
A10BH02 |
| DrugBank ID |
DB04876
|
| KEGG ID |
D07080
|
| MeSH ID |
D000077597
|
| PubChem ID |
5251896
|
| TTD Drug ID |
D0L3DK
|
| NDC Product Code |
50370-0032; 65372-1200; 69037-0028; 66651-102; 65727-051 |
| Synonyms |
Vildagliptin | (2S)-(((3-Hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile | NVP-LAF237 | NVP LAF237 | Galvus |
